A systematic review of recent outbreaks and the efficacy and safety of drugs approved for the treatment of Salmonella infections
Abstract
A systematic review was conducted to critically analyze the outbreaks, efficacy, and safety of drugs used to treat various Salmonella infections. Four drugs-azithromycin, ceftriaxone, ciprofloxacin, and amoxicillin-are commonly used to treat Salmonella infections, and all four drugs were included in this review. This review found that, of these, azithromycin and ceftriaxone were more effective in treating Salmonella infections based on the patient's length of stay in the hospital and the rate at which the fever was resolved. Fluoroquinolones are also effective in treating Salmonella infection but are not approved for use in children. Azithromycin was found to be the physicians' preferred choice of medication for Salmonella infection due to its less resistance development. Almost all these drugs produce varying degrees of adverse events, but they are mild to moderate. However, azithromycin was shown to be comparatively safer than the other three drugs in terms of side effects, adverse events, and relapse associated with Salmonella treatment. Developing effective and safe therapies for all strains of Salmonella remains a priority, especially given the increasing prevalence of antibiotic-resistant variants.
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.